Does Fenbendazole Really Work for Cancer? Evidence, Research & What Patients Should Know
Updated: Aug 25
Written by Dr. Adam Makis in TheSkyMeds Editorial Standards
Medically reviewed by Jonathan Reed, Medical Content Reviewer Mar 9 2026
Introduction
Online claims about fenbendazole for cancer often point to laboratory studies, animal experiments, and personal stories as evidence that this inexpensive veterinary deworming medicine can fight tumors. There is a real scientific reason for the interest: researchers have found that fenbendazole can interfere with cancer-cell growth through several biological pathways, including microtubules and glucose metabolism.
But those findings come mainly from cells and animals, not from controlled clinical trials proving benefit in people. Fenbendazole is not an FDA-approved human medicine or an established cancer treatment, and its safe dose, effectiveness, interactions, and long-term risks in people with cancer have not been adequately defined. Published reports have also documented serious liver injury after people self-administered fenbendazole. This article separates the promising preclinical research from the much weaker human evidence so patients can understand what science currently shows—and what it does not.
What Is Fenbendazole, and Why Is It Being Studied for Cancer?
Fenbendazole is a benzimidazole anthelmintic, meaning it is a drug designed to kill certain parasitic worms. It has established veterinary uses in animals, including dogs and other species, but it is not approved by the U.S. Food and Drug Administration for human use.
Interest in cancer developed because benzimidazole compounds can interact with structures and processes that rapidly dividing cells depend on.
The FDA information on veterinary fenbendazole products confirms that fenbendazole is used within veterinary medicine rather than as an FDA-approved human cancer drug.
Why cancer researchers became interested
Cancer cells often divide quickly and depend on structures called microtubules. Microtubules form part of the cell's internal framework and play an important role when cells divide.
Some well-established chemotherapy medicines also act on microtubules. That does not mean every substance affecting microtubules will become an effective chemotherapy drug, but it gives researchers a reason to investigate.
Fenbendazole has also been studied for possible effects on:
glucose uptake by cancer cells;
mitochondrial function;
cell-cycle progression;
programmed cell death, called apoptosis;
the tumor-suppressor protein p53; and
proteins involved in cell division.
These mechanisms help explain why fenbendazole can produce interesting results in experimental systems. They do not establish that a person taking veterinary fenbendazole will receive an anticancer benefit.
What Does Research on Fenbendazole for Cancer Actually Show?
Preclinical research shows that fenbendazole can inhibit or kill some cancer cells under laboratory conditions and suppress tumor growth in certain animal models. These findings justify further research, but they are not equivalent to evidence that fenbendazole improves cancer outcomes in humans.
Laboratory evidence
One frequently cited study was published in Scientific Reports in 2018. Researchers found that fenbendazole disrupted microtubule-related processes in cancer cells and affected several other pathways associated with cancer-cell survival.
The researchers reported reduced glucose uptake, changes involving the GLUT transporters and hexokinase II, and effects involving p53. Fenbendazole also produced cancer-cell death at concentrations used in the laboratory.
The 2018 Scientific Reports fenbendazole study is important because it provides a biological explanation for why the drug attracts cancer-research interest. It does not provide evidence that the same concentrations, effects, or clinical benefits occur safely in people.
Animal studies have produced mixed findings
The same 2018 research found that orally administered fenbendazole suppressed the growth of human cancer xenografts implanted in immunodeficient mice. A xenograft is an experimental model in which human tumor cells are grown in an animal.
Newer preclinical work has continued to generate interest. A 2025 study involving cervical cancer cell lines and mouse xenografts reported reduced tumor growth and effects on both cancer cells and experimentally defined cancer stem cells. Again, however, the study was conducted in laboratory and animal models rather than in patients.
Not every animal experiment has produced an encouraging result.
An earlier study examining fenbendazole in a mouse breast-cancer model found laboratory toxicity against tumor cells but reported that intensive fenbendazole treatment did not alter tumor growth or improve the effects of radiation. The authors concluded that their experiments did not provide evidence supporting fenbendazole's value as a cancer therapy.
Evidence level | What research has found | What it means | Main limitation |
Cancer cells in laboratory dishes | Fenbendazole can interfere with microtubules, glucose metabolism and cell survival in some models | The drug has biologically interesting anticancer activity | Laboratory concentrations may not be safely achievable in humans |
Mouse cancer models | Some experiments report slower tumor growth | Fenbendazole can have antitumor effects in certain whole-animal models | Mouse biology, metabolism and dosing do not directly predict human benefit |
Other animal experiments | Some have shown little or no meaningful tumor response | Results are not universally positive | Different tumors and experimental designs can produce different outcomes |
Human case reports | Individual people have reported responses while also receiving other treatments | They generate questions worth studying | They cannot establish that fenbendazole caused the response |
Controlled human cancer trials | Adequate evidence establishing efficacy is lacking | Clinical benefit remains unproven | Safe dosing, effectiveness and interaction risks remain uncertain |
Fenbendazole has enough biological activity to justify scientific investigation, but "kills cancer cells in a laboratory" and "treats cancer in patients" are very different claims. The human evidence needed to bridge that gap remains inadequate.
Does Fenbendazole Work for Cancer in Humans?
There is currently no reliable clinical evidence establishing fenbendazole as an effective cancer treatment in humans.
This is the most important distinction in the entire discussion.
A medicine intended for cancer treatment normally needs human studies that establish more than a biological mechanism. Researchers need to determine whether patients live longer, tumors shrink reliably, disease progression slows, symptoms improve, or another clinically meaningful outcome occurs without unacceptable toxicity.
Fenbendazole has not reached that standard.
A 2024 review discussing oral fenbendazole for cancer noted that human pharmacokinetics—the way the body absorbs, distributes, metabolizes, and eliminates a medicine—and human safety remain poorly documented. The authors argued that properly designed clinical trials are needed before its anticancer effects, tolerable dosing, and treatment schedules can be established.
The American Cancer Society stated in 2025 that fenbendazole has not been adequately tested in human cancer studies and that there is no scientific evidence establishing it as safe and effective for treating cancer in people.
The American Cancer Society review of fenbendazole also emphasizes that personal reports cannot determine whether improvement came from fenbendazole, standard cancer treatment, or another factor.
What about published patient case reports?
Case reports deserve attention, but their meaning must be interpreted carefully.
A 2025 publication described three people with advanced cancers who experienced substantial responses after incorporating fenbendazole while receiving other therapies. The cases are scientifically interesting, but they do not prove fenbendazole caused the outcomes because there was no untreated comparison group, participants were receiving other interventions, and case reports cannot control for competing explanations.
Case reports are normally considered hypothesis-generating evidence. They can justify further investigation but cannot establish effectiveness.
Randomized controlled trials are much more useful because researchers can compare patients receiving the experimental intervention with an appropriate control group while reducing bias and other explanations for improvement.
Why Don't Cancer Success Stories Prove Fenbendazole Works?
Personal cancer-remission stories can be emotionally compelling, but they cannot show whether fenbendazole caused the improvement.
Cancer patients commonly receive several interventions over the same period. These might include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, hormonal treatment, or participation in clinical trials.
If a person begins fenbendazole while also receiving an effective cancer treatment and their tumor later shrinks, there is no reliable way to know how much—if anything—fenbendazole contributed.
The well-known online problem of attribution
The American Cancer Society discusses a widely circulated story involving a man with lung cancer who credited fenbendazole with his improvement. However, during the same period he was participating in a clinical study involving immunotherapy that is an established treatment approach for his type of cancer.
That does not prove fenbendazole had no effect. It means the story cannot prove that it did.
Other limitations of online testimonials include:
medical records may not be available for independent review;
cancer type and stage may be incompletely reported;
standard treatments may receive less attention than the alternative remedy;
imaging changes may be interpreted without appropriate context;
unsuccessful experiences are less likely to become viral stories; and
spontaneous or unusually strong responses to established treatment can occur.
This is why cancer researchers rely on controlled clinical studies rather than collecting success stories alone.
"Drug repurposing" does not mean skipping clinical trials
Drug repurposing means investigating an existing medicine for a new use. This is a legitimate and important area of medical research.
Examples of older medicines eventually finding new therapeutic roles exist throughout medicine. But an interesting mechanism or low price does not remove the need for human studies.
Repurposed medicines still need evidence showing:
an appropriate human dose can be achieved;
drug exposure reaches the target tissue;
treatment has measurable clinical activity;
adverse effects are acceptable;
interactions with other cancer treatments are understood; and
benefits outweigh risks for a defined group of patients.
Fenbendazole has not yet cleared those evidence hurdles as a cancer therapy.
Is Fenbendazole Safe for People With Cancer?
Fenbendazole's safety in humans is not adequately established, and published cases show that significant liver injury can occur after self-administration.
Veterinary experience cannot establish human safety. The formulation, dosing, metabolism, cancer treatments being taken at the same time, and health of the individual can all affect risk.
Liver injury has been reported
A 2021 case report described an 80-year-old woman with advanced non-small cell lung cancer receiving pembrolizumab who developed severe liver injury after taking fenbendazole based on social-media information. Her liver abnormalities resolved after fenbendazole was stopped, and the report did not document tumor shrinkage from the drug.
Another report described a 67-year-old woman who developed severe, biopsy-confirmed drug-induced liver injury after self-administering veterinary fenbendazole. Her liver tests eventually normalized after she discontinued it.
More recently, a 2026 case involving a woman with metastatic colon cancer described severe hepatocellular liver injury after she increased her self-administered fenbendazole dose. A structured causality assessment identified fenbendazole as the probable cause, and liver tests improved after she stopped taking it.
The NIH LiverTox information on fenbendazole now describes fenbendazole as a veterinary anthelmintic not approved for humans and notes that clinically apparent acute liver injury can occur.
Unknown drug interactions are another concern
Cancer treatment frequently involves combinations of medicines with complex effects on the liver, immune system, bone marrow, blood clotting, or drug-metabolizing enzymes.
Because fenbendazole has not undergone adequate human oncology testing, clinicians do not have the same level of information available for established cancer drugs about:
safe combinations;
pharmacokinetic interactions;
effects on chemotherapy exposure;
interactions with immunotherapy;
effects on targeted medicines;
appropriate liver monitoring; or
safe management when toxicity develops.
Self-treatment can also complicate medical decisions. For example, abnormal liver tests in somebody taking immunotherapy might initially be interpreted as immune-related hepatitis when another substance is actually responsible.
Do | Don't |
Tell your oncologist about every medicine, supplement and veterinary product you are taking or considering | Do not hide fenbendazole use because you are worried the oncology team will disapprove |
Ask how strong the evidence is for any proposed experimental treatment | Do not treat testimonials as equivalent to clinical trials |
Discuss legitimate clinical-trial options if standard treatments are limited | Do not replace chemotherapy, immunotherapy, radiation, surgery or another prescribed therapy with fenbendazole |
Report jaundice, dark urine, unusual itching, persistent nausea or marked fatigue promptly | Do not assume veterinary experience proves safety in humans |
Use regulated pathways for experimental cancer treatments | Do not copy doses from social media, animal studies or online "protocols" |
Keep your cancer team informed about complementary approaches | Do not assume "repurposed drug" means proven or risk-free |
What Should Patients Do If They Are Considering Fenbendazole?
Patients interested in fenbendazole should discuss it openly with their oncology team rather than self-administering a veterinary product or replacing established treatment.
A good oncology discussion does not have to begin with an argument about whether an unconventional idea is "right" or "wrong." The more useful questions are about evidence, risk, interactions, and alternatives.
Patients may want to ask:
What type of evidence supports this treatment?
Have controlled human trials demonstrated benefit?
Could it interact with my current cancer therapy?
Could it affect my liver or other organs?
Would taking it make treatment side effects harder to interpret?
Are legitimate clinical trials available for my cancer?
Are there approved targeted therapies or immunotherapies relevant to my tumor's biomarkers?
The FDA warns that unproven products marketed as cancer cures can cause harm directly or by delaying treatments known to provide benefit. The agency recommends discussing experimental treatment options with licensed healthcare professionals and using legitimate research pathways such as clinical trials.
Experimental treatment is different from unsupervised treatment
Clinical trials exist precisely because researchers cannot know in advance whether a promising experimental therapy will work.
Early-phase trials generally focus heavily on safety and appropriate dosing. Later trials increasingly ask whether the treatment improves meaningful outcomes compared with established care.
That process can seem slow, especially to someone facing advanced cancer. But cancer drugs can produce serious toxicity, interact with other treatments, and sometimes look encouraging in early laboratory work before failing in patients.
Fenbendazole remains on the experimental side of that divide.
When to Seek Medical Advice or Urgent Care
Anyone with cancer who is currently taking fenbendazole without their oncology team's knowledge should tell the treating clinicians. That information can be important when interpreting symptoms, liver tests, medication interactions, and cancer-treatment side effects.
Contact a healthcare professional promptly if new symptoms develop after taking fenbendazole, particularly yellowing of the skin or eyes, dark urine, pale stools, persistent nausea or vomiting, unusual itching, upper abdominal pain, or marked fatigue. These symptoms can have many causes in people with cancer and require appropriate medical assessment rather than self-diagnosis.
Urgent medical evaluation may be necessary for severe confusion, fainting, uncontrolled vomiting, severe abdominal pain, difficulty breathing, major bleeding, or other rapidly worsening symptoms.
Most importantly, do not stop or postpone prescribed cancer treatment simply to try fenbendazole without discussing the consequences with the treating oncology team. Cancer therapy is highly individual, and interruptions can matter depending on the cancer type, stage, and treatment being given.
Conclusion
So, does fenbendazole for cancer really work? Laboratory and animal studies provide enough evidence to make fenbendazole scientifically interesting, but they have not established that it safely treats cancer in people. Human evidence remains limited largely to anecdotes and case reports, which cannot determine whether fenbendazole caused a tumor response, while published cases document potentially serious liver injury. Fenbendazole should therefore be viewed as an unproven experimental idea rather than a substitute for established cancer therapy. Patients interested in drug-repurposing approaches should discuss them with their oncology team and explore properly supervised clinical trials whenever available.
Frequently Asked Questions
1 . Has fenbendazole cured cancer in humans?
No reliable clinical evidence shows that fenbendazole cures cancer in humans. Individual remission stories and case reports cannot establish causation, especially when patients also receive recognized cancer treatments. Controlled human trials are needed to determine whether fenbendazole provides meaningful benefit.
2 . Why does fenbendazole kill cancer cells in laboratory studies?
Fenbendazole can interfere with microtubules and other processes involved in cancer-cell growth. Laboratory studies have also reported effects on glucose metabolism and cell-death pathways. These mechanisms make the drug scientifically interesting but do not prove clinical effectiveness in people.
3 . Is fenbendazole FDA approved for cancer?
No. Fenbendazole is used as a veterinary antiparasitic drug and is not FDA approved as a human cancer treatment. Regulatory approval requires evidence of appropriate quality, safety and effectiveness for a specific human use, which fenbendazole has not established for cancer.
4 . Are there clinical trials proving fenbendazole works for cancer?
No completed body of controlled human clinical evidence currently establishes fenbendazole as an effective cancer treatment. Most supportive research remains laboratory or animal based. Until adequate human trials report meaningful benefits and acceptable risks, its effectiveness remains uncertain.
5 . Can fenbendazole cause liver damage?
Yes, clinically significant liver injury has been reported in people who self-administered fenbendazole. Published cases include severe elevations in liver tests and biopsy-confirmed drug-induced liver injury. Anyone taking it who develops possible liver symptoms should seek medical assessment promptly.
6 . Can I take fenbendazole with chemotherapy or immunotherapy?
The safety of combining fenbendazole with cancer treatments has not been adequately established in human trials. Unknown interactions and overlapping liver toxicity are particular concerns. Patients considering it should discuss the issue with their oncology team rather than adding fenbendazole independently.
Comments